University of Massachusetts Medical School Faculty Publications

UMMS Affiliation

Department of Radiology

Publication Date


Document Type





Abstract Intraperitoneal (IP) injection is frequently reported to be as effective as intravenous (IV) injection. Because it allows administering a larger volume with more radioactivity, we have investigated this route and the possibility of using it to circumvent the volume constraint we earlier experienced with pretargeting radiotherapy. Using 99mTc as the label, the pharmacokinetics (PK) of the cMORF effector (a DNA analogue) was evaluated after IP or IV injection in normal mice by necropsy and SPECT/CT imaging. In another experiment, nude mice bearing tumors were used and they received MORF-CC49 pretargeting antibody IV 2 days earlier than labeled cMORF IV or IP. Tumor accumulations of cMORF were measured at 6 hours after its injections. The absorbed radiation doses for 188Re or 90Y pretargeting were estimated using the 99mTc data and a self-absorbed model. Although the absorbed radiation doses to other organs were comparable, the dose to intestines after IP injection was 30-fold higher than IV injection due to the slow entry into the circulation. It had reached such a level as high as the dose to the kidneys that cleared the radioactivity and usually were at the highest level. Nevertheless, the slow entry did not reduce the tumor accumulation. In conclusion, using IP in place of IV led to an unacceptably high absorbed radiation dose to the intestines although the tumor accumulation was not compromised. This effect may be applicable to other radiotherapeutic agents as well.


Intraperitoneal injection, IP injection, intravenous injection, IV injection

Rights and Permissions

This is a copy of an article published in the journal Cancer Biotherapy and Radiopharmaceuticals, copyright 2013 Mary Ann Liebert, Inc. Article is available online at: Publisher PDF posted as allowed by the publisher's author rights policy at

DOI of Published Version



Shuping Dou, Miles Smith, Yuzhen Wang, Mary Rusckowski, and Guozheng Liu. Cancer Biotherapy and Radiopharmaceuticals. May 2013, 28(4): 335-342. doi:10.1089/cbr.2012.1351. Link to article on publisher's site

Related Resources

Link to Article in PubMed

Journal/Book/Conference Title

Cancer biotherapy and radiopharmaceuticals

PubMed ID


Included in

Radiology Commons



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.